Interleukin-1 (IL-1) Inhibitor Pipeline Insights, 2019 Report - ResearchAndMarkets.com

January 25, 2019

DUBLIN--(BUSINESS WIRE)--Jan 25, 2019--The “Interleukin-1 (IL-1) Inhibitor - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Interleukin-1 (IL-1) Inhibitor - Pipeline Insight, 2019 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Interleukin-1 (IL-1) Inhibitor development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Clinical Non-clinical Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Interleukin-1 (IL-1) Inhibitor - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Interleukin-1 (IL-1) Inhibitor

The report assesses the active Interleukin-1 (IL-1) Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.

Scope of the report

Provides a snapshot of the therapeutics pipeline activity for Interleukin-1 (IL-1) Inhibitor Features the Interleukin-1 (IL-1) Inhibitor pipeline across the complete product development cycle including all clinical and non-clinical stages Offers detailed therapeutic product profiles of Interleukin-1 (IL-1) Inhibitor with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration Coverage of dormant and discontinued pipeline projects across Interleukin-1 (IL-1) Inhibitor

Companies Mentioned

Abbott Laboratories TWi Biotechnology Epitomics Apexigen Novartis Xbiotech Delenex Therapeutics Peptinov Regeneron Pharmaceuticals TRPHARM AB2 Bio Celgene Corporation Opsona Therapeutics DeuteRx Rigel Pharmaceuticals

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/nj5zfr/interleukin1?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190125005409/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Immune Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/25/2019 01:09 PM/DISC: 01/25/2019 01:09 PM


Update hourly